Last reviewed · How we verify
IncobotulinumtoxinA (75 Units)
IncobotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
IncobotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Hemifacial spasm.
At a glance
| Generic name | IncobotulinumtoxinA (75 Units) |
|---|---|
| Also known as | Xeomin, NT 201, Botulinum toxin type A (150 kiloDalton), free from complexing proteins |
| Sponsor | Merz Pharmaceuticals GmbH |
| Drug class | Botulinum toxin |
| Target | SNAP-25 (synaptosome-associated protein of 25 kDa) |
| Modality | Small molecule |
| Therapeutic area | Neurology, Dermatology, Aesthetics |
| Phase | Phase 3 |
Mechanism of action
IncobotulinumtoxinA is a botulinum toxin serotype A that irreversibly cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion and release. This prevents neuromuscular transmission, resulting in temporary paralysis of injected muscles. The effect is localized to the injection site and gradually reverses over 3-4 months as new nerve terminals form.
Approved indications
- Cervical dystonia
- Blepharospasm
- Hemifacial spasm
- Glabellar lines (dynamic wrinkles)
- Crow's feet
- Forehead lines
Common side effects
- Injection site pain or bruising
- Headache
- Muscle weakness or paralysis (off-target)
- Eyelid ptosis
- Dry mouth
- Neck pain
Key clinical trials
- Wearable Robotic System and Robotic Mirror Therapy in Spastic Hemiplegia Post Botulinum Toxin Injection (NA)
- Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy (PHASE3)
- Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IncobotulinumtoxinA (75 Units) CI brief — competitive landscape report
- IncobotulinumtoxinA (75 Units) updates RSS · CI watch RSS
- Merz Pharmaceuticals GmbH portfolio CI